Compare Adaptive Biotechnologies Corp (ADPT) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Gemini Space Station Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Gemini Space Station Inc trades at $4.02 (market cap $517.11M). The key difference: Adaptive Biotechnologies Corp is far larger — about 7.8× Gemini Space Station Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | GEMI | |
|---|---|---|
Market Cap | $4.05B | $517.11M |
Sector | Health | Technology |
52-Week High | $25.45 | $32.52 |
52-Week Low | $12.30 | $3.90 |
Enterprise Value | $4.12B | $507.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
GEMI trades at $4.09, up 2.76% today, but remains in a bearish technical trend with support and resistance clustered at $4. The company reported a net loss of $582.81 million in 2025, with negative margins and cash flow from operations, while revenue grew to $179.57 million. Recent news includes a $100 million investment from Winklevoss Capital and multiple securities class action lawsuits filed in May 2026.
The outlook is highly speculative with significant operational losses and legal overhangs, though analyst consensus suggests a $6.33 price target. Investment opportunity hinges on turnaround execution and super app adoption, but risks include persistent unprofitability, competitive pressure, and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
